Patents by Inventor Caroline Durand

Caroline Durand has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NHE-1 INHIBITORS FOR THE TREATMENT OF CORONAVIRUS INFECTIONS
    Publication number: 20240041804
    Abstract: The present invention encompasses NHE-1 inhibitors for use in the treatment of coronavirus infections, including COVID-19, alone or in combination with one or more additional therapeutic agents.
    Type: Application
    Filed: August 24, 2021
    Publication date: February 8, 2024
    Inventors: FLORENCE PORTE THOME, CAROLINE KANT MAREDA, CAROLINE DURAND AVALLONE, JIRI MAREDA, SAMEERA ALLIE
  • Passive immunisation against influenza, in particular H5N1
    Patent number: 9975945
    Abstract: The invention relates to a composition comprising immunoglobulins specific to influenza virus and produced through immunization of a producer animal, for use as a medicament for the passive immunization of a human against an infection by an influenza virus, wherein the medicament is administered to the human in at least 1 dose before exposition or risk of exposition to an influenza virus and/or after exposition or risk of exposition to an influenza virus, and wherein the overall amount administered to the human in one or more doses is at least 20 ?g of immunoglobulins per kg body weight. When the composition is for use after exposition or risk of exposition to an influenza virus, it is preferably administered to the human in at least 2 doses after exposition or risk of exposition to an influenza virus.
    Type: Grant
    Filed: September 30, 2013
    Date of Patent: May 22, 2018
    Assignee: FABENTECH
    Inventors: Bertrand Lepine, Laurent Vacher, Caroline Durand, Cécile Herbreteau-Delale
  • Passive Immunisation Against Influenza, In Particular H5N1
    Publication number: 20150299297
    Abstract: The invention relates to a composition comprising immunoglobulins specific to influenza virus and produced through immunization of a producer animal, for use as a medicament for the passive immunisation of a human against an infection by an influenza virus, wherein the medicament is administered to the human in at least 1 dose before exposition or risk of exposition to an influenza virus and/or after exposition or risk of exposition to an influenza virus, and wherein the overall amount administered to the human in one or more doses is at least 20 ?g of immunoglobulins per kg body weight. When the composition is for use after exposition or risk of exposition to an influenza virus, it is preferably administered to the human in at least 2 doses after exposition or risk of exposition to an influenza virus.
    Type: Application
    Filed: September 30, 2013
    Publication date: October 22, 2015
    Applicant: Fabentech
    Inventors: Bertrand Lepine, Laurent Vacher, Caroline Durand, Cécile Herbreteau-Delale